Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 12:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–7 of 7 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Human Influenza
Interventions
Recombinant Influenza Vaccine, Inactivated Influenza Vaccine
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
254,648 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Oakland, California
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults

NCT06237049
Conditions
Influenza, Human, SARS-CoV-2 Infection, COVID-19
Interventions
BNT162b2 (Omi XBB.1.5)/RIV, BNT162b2 (Omi XBB.1.5), RIV, Normal saline placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
644 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
30
States / cities
Lake Forest, California • Tustin, California • Walnut Creek, California + 22 more
Conditions
Influenza
Interventions
Quadrivalent RIV with H3 strain 1, Quadrivalent RIV with H3 strain 2, Quadrivalent RIV with H3 strain 3, Quadrivalent RIV with H3 strain 4, Quadrivalent RIV with 2018-2019 NH H3 strain
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 30 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Hollywood, Florida • Rochester, New York • North Charleston, South Carolina
Conditions
Influenza Immunisation, Healthy Volunteers
Interventions
Quadrivalent RIV with H3 strain 1, Quadrivalent RIV with H3 strain 1 and adjuvant, Quadrivalent RIV with H3 strain 2, Quadrivalent RIV with H3 strain 2 and adjuvant, Quadrivalent RIV with 2018-2019 NH H3 strain, Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
5
States / cities
San Diego, California • Melbourne, Florida • Orlando, Florida + 2 more
Conditions
COVID-19 Immunization, Influenza Immunization
Interventions
RIV (recombinant influenza vaccine), rC19 (dose 1), RIV + rC19 (dose 1), RIV + rC19 (dose 2), RIV + rC19 (dose 3), RIV + rC19 (dose 4), Placebo (0.9% NaCl)
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
980 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • Cerritos, California • Vista, California + 9 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety of RIV4 Versus IIV4 in Pregnant Women

NCT03969641
Conditions
Safety, Adverse Event Following Immunisation, Birth Outcomes
Interventions
Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
384 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Durham, North Carolina • Cincinnati, Ohio
Conditions
Influenza, Human
Interventions
Fluzone Quadrivalent, Flublok Quadrivalent
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 64 Years
Enrollment
3,988 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Tucson, Arizona • Tallahassee, Florida • Houston, Texas + 1 more